Results 31 to 40 of about 1,166,657 (155)

Serological Evidence of Potential Marburg Virus Circulation in Livestock and Dogs in Ghana

Pathogens
Marburg virus disease (MVD) is a zoonotic hemorrhagic disease with an estimated case fatality rate of up to 88%. Ghana recorded its first human MVD outbreak in June 2022 and although the outbreak was quickly brought under control, the transmission ...
Theophilus Odoom, Sherry Ama Mawuko Johnson, William Tasiame, Meyir Y. Ziekah, Joseph K. Abuh, Benita Anderson, Fenteng Danso, Richard K. Abbiw, Franklin Y. Nuokpem, Emmanuel Allegye-Cudjoe, Charles Lewis, Bonto Faburay   +11 more
doaj   +3 more sources

Marburg Virus VP30 Is Required for Transcription Initiation at the Glycoprotein Gene

mBio, 2022
Marburg virus (MARV) is an enveloped, negative-sense RNA virus from the filovirus family that causes outbreaks of severe, frequently fatal illness in humans. Of the seven MARV proteins, the VP30 protein stands out because it is essential for viral growth
Megan R. Edwards, Olivia A. Vogel, Hiroyuki Mori, Robert A. Davey, Christopher F. Basler   +4 more
doaj   +1 more source

Rapid and Durable Protection Against Marburg Virus with a Single-Shot ChAd3-MARV GP Vaccine [PDF]

, 2021
Abstract Marburg virus (MARV) causes a severe hemorrhagic fever disease in primates with mortality rates in humans up to 90%. Since 2018, MARV has been identified as a priority pathogen by the WHO, needing urgent research and development of countermeasures due to the high public health risk it poses.
Ruth Hunegnaw, Anna Honko, Lingshu Wang, Derick Carr, Tamar Murray, Wei Shi, Caitlyn N. M. Dulan, Kathryn E. Foulds, Krystle N. Agans, Robert W. Cross, Joan B. Geisbert, Thomas W. Geisbert, Cheng Cheng, Aurélie Ploquin, Daphne A. Stanley, Gary J. Nabel, Nancy J. Sullivan   +16 more
openaire   +1 more source

Advancements in Marburg (MARV) Virus Vaccine Research With Its Recent Reemergence in Equatorial Guinea and Tanzania: A Scoping Review

Cureus, 2023
Given the recent outbreaks of the Marburg (MARV) virus within the first quarter of the year 2023, interest in the MARV virus has been re-ignited given its shared phylogeny with the dreadful Ebola virus. This relation gives some insight into its virulence, associated morbidities, and mortality rates.
Mane Manohar, Manish P, Lee, Vivian J, Chinedum Odunukwe, Ejikeme U, Singh, Pratik K, Mpofu, Buhlebethu S, Oxley, MD, Christine   +5 more
openaire   +2 more sources

Systematic Review on Marburg Virus Prevalence and Persistence in Animals [PDF]

Frontiers in Veterinary Science
Sherihane Aryeetey, Raphaël Folitse, John Amuasi   +2 more
exaly   +2 more sources

Comparison of EBOV and MARV pathophysiology over time.

, 2022
EBOV, Ebola virus; MARV, Marburg virus; NHP, nonhuman primate.
Christopher D. Kane (8592750), David L. Saunders (8699277), Catherine A. Bigger (12213596), Patrick L. Iversen (12213599), Mark R. Hickman (8951750)   +4 more
core   +1 more source

Knowledge, Attitudes, and Practices Regarding Marburg Virus Disease Among Healthcare Workers in Dilla University Teaching Hospital, Ethiopia: A Cross-Sectional Study. [PDF]

Can J Infect Dis Med Microbiol
Background Healthcare workers are a first contact for patients with infectious diseases and may be at occupational risk during hemorrhagic fever outbreaks. The Marburg virus disease (MVD) outbreak in southern Ethiopia, ongoing during data collection in December 2025, highlighted the need to assess healthcare workers’ knowledge, attitudes, and practices
Demeke AD, Tamir T, Abebe M, Endawoke M, Goshu AS, Dube SJ, Amede ES, Eba WW, Molatu AT, Yeshiwas A, Akele MA, Bayable A.   +11 more
europepmc   +2 more sources

Immunogenic and Protective Features of the Recombinant Vaccinia Virus Strain Expressing Cassette of Genes of Marburg Virus Structural Proteins

Проблемы особо опасных инфекций, 2022
The aim of the study was to create a highly immunogenic vaccine construct based on a recombinant variant of a replication-defective MVA strain of vaccinia virus, expressing virus-like particles that mimic natural infection with Marburg virus.
A. V. Semenova, G. F. Sivolobova, A. A. Grazhdantseva, S. A. P’yankov, I. S. Shul’gina, O. S. Taranov, O. V. P’yankov, D. V. Antonets, L. I. Karpenko, E. V. Starostina, M. V. Borgoyakova, A. N. Chikaev, E. V. Gavrilova, R. A. Maksyutov, G. V. Kochneva   +14 more
doaj   +1 more source

Regulation of Marburg virus (MARV) budding by Nedd4.1: a different WW domain of Nedd4.1 is critical for binding to MARV and Ebola virus VP40

Journal of General Virology, 2009
The VP40 matrix protein of Marburg virus (MARV) has been shown to be the driving force behind MARV budding, a process in which the PPPY L-domain motif of VP40 plays a critical role. Here, we report that Vps4B and Nedd4.1 play critical roles in MARV VP40-mediated budding.
Shuzo, Urata, Jiro, Yasuda
openaire   +2 more sources

Obtaining Recombinant Antigens for the Development of Serological Diagnosis of Marburg Fever

Проблемы особо опасных инфекций, 2021
Aim. Production of recombinant viral antigens of the main immunodominant proteins: glycoprotein (GPΔMLD), nucleoprotein (NP) and matrix protein (VP40) of the Marburg virus, as well as the study of their antigenic and immunogenic properties.Materials and ...
N. V. Volkova, A. V. Ivanova, A. A. Isaeva, O. A. Polezhaeva, A. V. Zaykovskaya, D. N. Shcherbakov, E. I. Kazachinskaya   +6 more
doaj   +1 more source